Roche to buy gene therapy specialist Spark in US $ 4.3 billion deal
Health
Roche on Monday said it will buy Spark Therapeutics in a transaction valued at US $ 4.3 billion as the Swiss drug maker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.
FILE PHOTO – The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS / Arnd Wiegmann
ZURICH: Roche on Monday said it will buy Spark Therapeutics in a transaction valued at US $ 4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis. 19659008] Roche will acquire US-based Spark for US $ 114.50 per share, with premium of about 122 percent to Spark's closing price on Feb.
(Reporting by John Miller; editing by Thomas Seythal)
